Live Breaking News & Updates on At Ose Fr0012127173
Stay updated with breaking news from At ose fr0012127173. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NANTES, France, Feb. 23, 2021 (GLOBE NEWSWIRE) OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of the Company’s business at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-11, 2021. The presentation will be available for on-demand listening beginning March 9 at 7:00 am (EST) / 1:00 pm (CET) and archived for 90 days. Webcasting link: ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile: ....